Mandate

Vinge advises Infranity in connection with the acquisition of Nordic Re-Finance AB

Vinge has advised Infranity, a private equity firm specializing in infrastructure investments, in connection with its acquisition of a majority stake in Nordic Re-Finance AB, a Scandinavian locomotives lessor. The acquisition brings ambitious development plans for Nordic Re-Finance AB, including expansion into new geographical areas.

The transaction is subject to regulatory approvals and is expected to close in Q1 2025.

Vinge’s team consisted of among other Matthias Pannier, Ulrich Ziche, Robin Sultani and Sara Hammond (M&A), Calle Tengwall Pagels and Julia Gudmundsson (Banking and Finance, Jolene Reimerson, Christoffer Nordin, Katja Häglund and Nicklas Thorgerzon (Commercial Contracts, IT and GDPR), Victor Ericsson, Erik Kochbati, Tobias Fleischer, Ellenor Eckerborn and Marcus Svärd (Tax), Alice Göransson and Gulestan Ali (Employment), Tobias Kempas and Rebecka Målquist (IP), Daniel Wendelsson, Alva Chambert and Martin Hammarskiöld (FDI) and Julia Ulander Kull (Transaction Support).

Related

Vinge advises OsteoCentric on the public offer for Integrum

OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025